Hypnotic doses of such barbiturates usually do not show up to considerably impair uterine activity during labor; full anesthetic doses of barbiturates reduce the force and frequency of uterine contractions; administration of sedative-hypnotic barbiturates into the mother during labor may well lead to respiratory despair during the newborn
pentobarbital will lessen the extent or outcome of rabeprazole by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Not known.
Caution when discontinuing CYP3A4 inducers which can be coadministered with benzhydrocodone (prodrug of hydrocodone); plasma concentrations of hydrocodone might improve and can result in likely deadly respiratory depression.
pentobarbital will lower the level or result of eltrombopag by influencing hepatic enzyme CYP2C9/ten metabolism. Use Warning/Check.
pentobarbital will lower the level or impact of almotriptan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
pentobarbital will lessen the level or outcome of colchicine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.
pentobarbital will lessen the level or result of darunavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
Medications that have amount limits associated with Each individual prescription. This restriction commonly limits the amount in the drug that will be coated.
buprenorphine subdermal implant and pentobarbital each raise sedation. Prevent or Use Alternate Drug. Limit use to patients for whom option procedure possibilities are insufficient
pentobarbital will minimize the level or impact of lapatinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
If inducer is discontinued, contemplate oliceridine dosage reduction and keep track of for signs of respiratory depression.
Monitor Intently (1)pentobarbital will lower the extent or outcome of fentanyl intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Carefully. Coadministration of fentanyl with CYP3A4 inducers could lead to the lower in fentanyl plasma concentrations, insufficient efficacy or, possibly, enhancement of a withdrawal syndrome in a client that has made Bodily dependence to fentanyl. After stopping a CYP3A4 inducer, as the consequences in the inducer drop, the fentanyl plasma concentration will raise which could improve or extend both the therapeutic and adverse outcomes.
pentobarbital will minimize the extent or outcome of dutasteride by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Unknown.
pentobarbital here will lower the level or influence of fentanyl transmucosal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep track of Closely. Coadministration of fentanyl with CYP3A4 inducers could lead to a lessen in fentanyl plasma concentrations, deficiency of efficacy or, possibly, advancement of a withdrawal syndrome in a very client who's got produced physical dependence to fentanyl.